This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Down -24.71% in 4 Weeks, Here's Why You Should You Buy the Dip in Health Catalyst (HCAT)
by Zacks Equity Research
Health Catalyst (HCAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Compelling Reasons to Hold Acadia Healthcare (ACHC) Stock Now
by Zacks Equity Research
Growing commercial, Medicare and Medicaid revenues will likely boost Acadia Healthcare's (ACHC) top line.
Humana's (HUM) Medicaid Business Teams Up With CPESN USA in Ohio
by Zacks Equity Research
Humana's (HUM) partnership with CPESN USA in Ohio aims to overcome barriers like limited access to healthcare services in rural and underserved communities.
Select Medical (SEM) Expands in Florida With UF Health JV
by Zacks Equity Research
Select Medical (SEM) inks a joint venture agreement with UF Health Jacksonville to open a 48-bed inpatient rehabilitation hospital in Florida.
UnitedHealth's (UNH) Optum to Buy Steward's Physician Group
by Zacks Equity Research
UnitedHealth (UNH) unit Optum's acquisition of Steward Health's physician group is expected to close in the second quarter of 2024.
Wall Street Analysts Think Health Catalyst (HCAT) Could Surge 53.65%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Health Catalyst (HCAT) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
3 Medical Info Systems Stocks to Buy as Industry Improves
by Urmimala Biswas
A few Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Talkspace (TALK) and Health Catalyst (HCAT) are expected to gain from the new normal trends.
Select Medical's (SEM) Concentra Submits Confidential IPO Filing
by Zacks Equity Research
The move from Select Medical's (SEM) Concentra highlights the recovery in the U.S. IPO market, especially for healthcare companies.
Evaluating Molina Healthcare's (MOH) Future View: Hold or Fold?
by Zacks Equity Research
Molina Healthcare's (MOH) top line is poised to gain from rising premium revenues and investment income.
Why Elevance (ELV) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Elevance's (ELV) top line is poised to gain from rising product revenues, administrative fees and other revenues.